Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN SODIUM versus LAROTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN SODIUM versus LAROTID.
AMPICILLIN SODIUM vs LAROTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
1-2 g IV/IM every 4-6 hours for serious infections; maximum 12 g/day.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
None Documented
None Documented
Terminal elimination half-life ~1 hour in healthy adults; prolonged to 2–5 hours in renal impairment (CrCl <10 mL/min) and up to 7–20 hours in anuria; neonatal half-life 2–4 hours.
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Approximately 90% renal excretion via tubular secretion and glomerular filtration; small biliary excretion (<10%); fecal elimination negligible.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic